Company Filing History:
Years Active: 2025
Title: Innovations of Liwei Mu in JAK Kinase-Related Diseases
Introduction
Liwei Mu is a prominent inventor based in Guangdong, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of drugs targeting JAK kinase-related diseases. His innovative work has led to the filing of a patent that showcases his expertise and dedication to improving healthcare.
Latest Patents
Liwei Mu holds a patent for the "Use of JAK inhibitors in preparation of drugs for treating JAK kinase-related diseases." This patent discloses the use of a JAK inhibitor [1,2,4]-triazolo-[1,5-a]pyridine compound in the preparation of drugs aimed at treating autoimmune, inflammatory, or allergic diseases, as well as conditions such as transplant rejection. The compound, which includes isomers and pharmaceutically acceptable salts, has demonstrated good efficacy in animal model tests for these diseases. He has 1 patent to his name.
Career Highlights
Liwei Mu is currently associated with Zhuhai United Laboratories Co., Ltd., where he continues to advance his research and development efforts. His work is characterized by a commitment to innovation and a focus on addressing critical health challenges through effective pharmaceutical solutions.
Collaborations
Liwei Mu collaborates with notable colleagues, including Shuai Wang and Degang Wang, who contribute to his research endeavors. Their combined expertise enhances the potential for groundbreaking discoveries in the field of drug development.
Conclusion
Liwei Mu's contributions to the pharmaceutical industry, particularly through his patent on JAK inhibitors, highlight his role as an influential inventor. His work not only showcases his innovative spirit but also promises to make a significant impact on the treatment of various diseases.